


Glycemic Control Algorithm for Type 2 Diabetes Mellitus In Adults^{1,6}



Footnotes

¹ Powers MA et al. Diabetes self management and education support in type 2 DM. Diabetes Care 2015;38:1372-1382

² If initial A1c on presentation is ≥10%, consider insulin, with or without oral agents, as the initial intervention (see Insulin Algorithm)

³ These interventions should be maintained life-long (refer to Medical Nutrition, Weight Loss, and Exercise Algorithms)

⁴ Dose is reduced based on either serum creatinine (metformin, DPP4i's) or calculated/estimated glomerular filtration rates (SGLT2i's)

⁵ If a SU is selected, glipizide ER or glimepiride are recommended because they have a lower incidence of hypoglycemia than glyburide

⁶ SGLT-2 inhibitors are not indicated if the glomerular filtration rate is less than 40%

⁷ See package insert for drug contraindications and warnings.

⁸ See Insulin Algorithm

GLYCEMIC CONTROL BIBLIOGRAPHY

Recent Review Articles

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes 2015: A patient-centered approach. *Diabetes Care* 2015;38(1):140-149.

Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. *JAMA*. 2002;287(3):360-72.

Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. *Circulation*. 2008 Jan 29;117(4):574-84.

Riddle, MC. Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins and combinations. *Endocrinol Metab Clin N Am*. 2005;34(1):77-98.

Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. *Diabetes Care*. 2010 Feb;33(2):428-33.

Dual Therapy**Empagliflozin + Linagliptin**

DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. *Diabetes Care* 2015;38:384–393.

Metformin or Sulfonylurea + Acarbose

Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. *Ann Intern Med*. 1994;121(12):928-35.

Metformin + Pioglitazone

Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. *Clin Ther*. 2000;22(12):1395-409.

Metformin + Rosiglitazone

Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. *JAMA*. 2000;283(13):1695-702. Erratum in: *JAMA* 2000;284(11):1384.

Sulfonylurea + Pioglitazone

Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. *Am J Med*. 2001;111(1):10-7.

Sulfonylurea + Rosiglitazone

Wolffenbittel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. *Diabet Med*. 2000;17(1):40-7.

Metformin or Sulfonylurea + Exenatide

Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care*. 2004;27(11):2628-35.

DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care*. 2005;28(5):1092-100.

Nateglinide or Repaglinide + Metformin

Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. *Diabetes Care*. 2003;26(7):2063-8. Erratum in: *Diabetes Care*. 2003;26(9):2708.

Repaglinide + Metformin

Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care*. 1999;22(1):119-24.

Nateglinide + Metformin

Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. *Diabetes Care*. 2000;23(11):1660-5.

Nateglinide + Thiazolidinedione

Rosenstock J, Shen SG, Gatlin MR, et al. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. *Diabetes Care*. 2002;25(9):1529-33.

Fonseca V, Grunberger G, Gupta S, et al. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. *Diabetes Care*. 2003;26(6):1685-90.

Repaglinide + Thiazolidinedione

Raskin P, Jovanovic L, Berger S, et al. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. *Diabetes Care*. 2000;23(7):979-83.

Liraglutide + Metformin

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care*. 2009 Jan;32(1):84-90.

Liraglutide + Sulfonylurea

Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). *Diabet Med*. 2009 Mar;26(3):268-78.

GLYCEMIC CONTROL BIBLIOGRAPHY (CONT.)

Triple Therapy**Metformin + Saxagliptin + Dapagliflozin**

Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. *Diabetes Care* 2015;38:376–383.

Sulfonylurea + Metformin + Alpha glucosidase inhibitors

Lam KS, Tiu SC, Tsang MW, et al. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. *Diabetes Care*. 1998;21(7):1154-8.

Standl E, Schernthaner G, Rybka J, et al. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. *Diabetes Res Clin Pract*. 2001;51(3):205-13.

Sulfonylurea + Metformin + Thiazolidinedione

Dailey GE 3rd, Noor MA, Park JS, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.

Am J Med. 2004;116(4):223-9.

Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. *Am J Med*. 2004;116(4):230-5.

Sulfonylurea + Metformin + Exenatide

Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care*. 2005;28(5):1083-91.

Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized study. *Ann Intern Med*. 2005; 143(8):559-69.

Liraglutide + Metformin and TZD

Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). *Diabetes Care*. 2009 Jul;32(7):1224-30.

Liraglutide + Metformin and Sulfonylurea

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. *Diabetologia*. 2009 Oct;52(10):2046-55.